Agenus. has filed a patent for antibodies targeting CD73 to inhibit its function, potentially treating various conditions. The patent also includes sequences for heavy and light chain variable regions of the antibodies. GlobalData’s report on Agenus gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Agenus Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Agenus, Personalized cancer vaccines was a key innovation area identified from patents. Agenus's grant share as of January 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

Antibodies binding to cd73 for treating subjects

Source: United States Patent and Trademark Office (USPTO). Credit: Agenus Inc

A recently filed patent (Publication Number: US20230416397A1) discloses a series of claims related to isolated polynucleotides encoding heavy chain variable regions or light chain variable regions of antibodies. These polynucleotides contain specific amino acid sequences for complementarity determining regions (CDRs) in both the heavy and light chain variable regions. The patent outlines various combinations of amino acid sequences for CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, along with corresponding SEQ ID numbers for reference.

Furthermore, the patent details additional claims related to the composition of antibodies, including specific amino acid sequences for heavy and light chain variable regions, as well as mutations and specific constant regions for the heavy chain. The patent also covers the inclusion of TGFß-binding and VEGF-binding moieties in the polynucleotides, along with peptide linkers and specific amino acid sequences for these binding moieties. Additionally, the patent discusses the use of vectors containing these polynucleotides, recombinant host cells expressing these polynucleotides, and methods for producing antibodies using these host cells under suitable conditions. Overall, the patent provides a comprehensive overview of the isolated polynucleotides and their applications in antibody production.

To know more about GlobalData’s detailed insights on Agenus, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies